11 unknown, 1 recruiting. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Unknown 9 |
| Phase 2 | 5 | Unknown 4, Recruiting 1 |
Follow Maxinovel Pty., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia MAX-40279, Azacitidine, Venetoclax - Acute Myeloid Leukemia | Phase 2 | Recruiting | Maxinovel Pty., Ltd. | 43 | 2025-09-05 | 2026-08-03 |
| A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors MAX-40279-01: 50mg/70mg - Advanced / Metastatic Solid Tumors | Phase 1 / Phase 2 | Unknown | Maxinovel Pty., Ltd. | 108 | 2022-07-31 | 2022-06-21 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer MAX-40279 - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Unknown | Maxinovel Pty., Ltd. | 30 | 2022-06-01 | 2022-06-02 |
| A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors "MAX-40279-01" and "Toripalimab" - Solid Tumor | Phase 1 | Unknown | Maxinovel Pty., Ltd. | 28 | 2022-04-11 | 2022-05-11 |
| A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects MAX-40070, Placebo - Alopecia Areata | Phase 1 | Unknown | Maxinovel Pty., Ltd. | 78 | 2022-02-28 | 2022-01-19 |
| A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer MAX-40279-01, regorafenib - Metastatic Colorectal Cancer | Phase 2 | Unknown | Maxinovel Pty., Ltd. | 130 | 2022-01-31 | 2021-12-06 |
| A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) MAX-40279-01 - Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Maxinovel Pty., Ltd. | 100 | 2021-09-16 | 2021-10-01 |
| MAX-10181 in Patients With Advanced Solid Tumor MAX-10181 - Solid Tumor | Phase 1 | Unknown | Maxinovel Pty., Ltd. | 80 | 2021-08-11 | 2022-01-19 |
| MAX-10181 Given Orally to Patients With Advanced Solid Tumor MAX-10181 - Solid Tumor | Phase 1 | Unknown | Maxinovel Pty., Ltd. | 30 | 2020-02-11 | 2022-01-19 |
| MAX-40279-01 in Patients With Advanced Solid Tumors MAX-40279-01 - Solid Tumor | Phase 1 | Unknown | Maxinovel Pty., Ltd. | 30 | 2019-11-28 | 2022-01-19 |
| Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) MAX-40279-01 - AML | Phase 1 | Unknown | Maxinovel Pty., Ltd. | 30 | 2019-04-16 | 2022-01-19 |
| MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) MAX-40279 - Acute Myelogenous Leukemia (AML) | Phase 1 | Unknown | Maxinovel Pty., Ltd. | 30 | 2018-08-01 | 2022-01-19 |
Leukemia, Myeloid, Acute (3) · Alopecia Areata (1) · Colorectal Neoplasms (1) · Leukemia (1) · Myelodysplastic Syndromes (1) · Stomach Neoplasms (1)
Azacitidine (2) · regorafenib (1) · toripalimab (1) · venetoclax (1)
China (8) · Australia (2)
Jianxiang Wang, MD (1) · Yonghong Zhu, MD,Ph.D (1)